NZ588374A - Tetrazole compounds for reducing uric acid - Google Patents
Tetrazole compounds for reducing uric acidInfo
- Publication number
- NZ588374A NZ588374A NZ588374A NZ58837409A NZ588374A NZ 588374 A NZ588374 A NZ 588374A NZ 588374 A NZ588374 A NZ 588374A NZ 58837409 A NZ58837409 A NZ 58837409A NZ 588374 A NZ588374 A NZ 588374A
- Authority
- NZ
- New Zealand
- Prior art keywords
- uric acid
- tetrazole
- compounds
- dimethylbenzyloxy
- formula
- Prior art date
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract 3
- 229940116269 uric acid Drugs 0.000 title abstract 3
- -1 Tetrazole compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 201000001431 Hyperuricemia Diseases 0.000 abstract 2
- JYXZNKDUAFJFDE-UHFFFAOYSA-N 5-[2-[3-[(2,6-dimethylphenyl)methoxy]phenyl]ethyl]-2h-tetrazole Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(CCC=2NN=NN=2)=C1 JYXZNKDUAFJFDE-UHFFFAOYSA-N 0.000 abstract 1
- CWUFRHCAHLQODO-UHFFFAOYSA-N 5-[[3-[(2,6-dimethylphenyl)methoxy]-4-methoxyphenyl]methyl]-2h-tetrazole Chemical compound C1=C(OCC=2C(=CC=CC=2C)C)C(OC)=CC=C1CC1=NN=NN1 CWUFRHCAHLQODO-UHFFFAOYSA-N 0.000 abstract 1
- PVTBFAKZJRWPNC-UHFFFAOYSA-N 5-[[3-[(2,6-dimethylphenyl)methoxy]-4-methylphenyl]methyl]-2h-tetrazole Chemical compound C1=C(OCC=2C(=CC=CC=2C)C)C(C)=CC=C1CC1=NN=NN1 PVTBFAKZJRWPNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000007530 Essential hypertension Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000000913 Kidney Calculi Diseases 0.000 abstract 1
- 206010029148 Nephrolithiasis Diseases 0.000 abstract 1
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008085 renal dysfunction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4916708P | 2008-04-30 | 2008-04-30 | |
| US9374308P | 2008-09-03 | 2008-09-03 | |
| PCT/US2009/042298 WO2009134995A2 (en) | 2008-04-30 | 2009-04-30 | Tetrazole compounds for reducing uric acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ588374A true NZ588374A (en) | 2012-11-30 |
Family
ID=41255799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ588374A NZ588374A (en) | 2008-04-30 | 2009-04-30 | Tetrazole compounds for reducing uric acid |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8410154B2 (https=) |
| EP (1) | EP2282736B1 (https=) |
| JP (1) | JP5431457B2 (https=) |
| KR (1) | KR101613611B1 (https=) |
| CN (1) | CN102014898B (https=) |
| AU (1) | AU2009243028B2 (https=) |
| BR (1) | BRPI0910541B8 (https=) |
| CA (1) | CA2722624C (https=) |
| ES (1) | ES2561039T3 (https=) |
| IL (1) | IL209004A (https=) |
| MX (1) | MX2010011603A (https=) |
| NZ (1) | NZ588374A (https=) |
| RU (1) | RU2522458C2 (https=) |
| WO (1) | WO2009134995A2 (https=) |
| ZA (1) | ZA201006929B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5339545B2 (ja) | 2008-03-13 | 2013-11-13 | ウェルスタット セラピューティクス コーポレイション | 尿酸を減少させる化合物及び方法 |
| MX2010011603A (es) | 2008-04-30 | 2011-01-25 | Wellstat Therapeutics Corp | Compuestos de tetrazol para reducir el acido urico. |
| WO2011046800A1 (en) * | 2009-10-13 | 2011-04-21 | Wellstat Therapeutics Corporation | 3-substituted compounds for reducing uric acid |
| WO2012033720A1 (en) * | 2010-09-08 | 2012-03-15 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
| MY180138A (en) | 2011-11-03 | 2020-11-23 | Ardea Biosciences Inc | 3,4-di-substituted pyridine compound,methods of using and compositions comprising the same |
| PL2775836T3 (pl) * | 2011-11-04 | 2019-02-28 | Cymabay Therapeutics, Inc. | Sposoby leczenia zaostrzeń dny moczanowej |
| BR112014017902A2 (pt) * | 2012-01-27 | 2017-08-22 | Teijin Pharma Limited E National Univ Corporation Tottori Univ | Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose |
| TW201443025A (zh) * | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| CN104262277B (zh) * | 2014-10-07 | 2016-06-22 | 张远强 | 含硝基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 |
| CN104292177B (zh) * | 2014-10-07 | 2016-08-17 | 张远强 | 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 |
| CN104292176B (zh) * | 2014-10-07 | 2016-06-29 | 张远强 | 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途 |
| JP6192142B2 (ja) * | 2016-09-13 | 2017-09-06 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 痛風発赤の治療方法 |
| RU2683570C1 (ru) * | 2018-05-23 | 2019-03-29 | Евгений Иванович Верещагин | Композиция из растительных компонентов, обладающая способностью снижать уровень мочевой кислоты сыворотки крови |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN114805233A (zh) * | 2022-03-30 | 2022-07-29 | 华南理工大学 | 苯基四氮唑类xor抑制剂及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4021556A (en) | 1972-06-08 | 1977-05-03 | Icn Pharmaceuticals, Inc. | Xanthine oxidase inhibitors |
| US4024253A (en) | 1973-04-20 | 1977-05-17 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Treatment of elevated histamine and uric acid levels |
| US4182764A (en) | 1973-10-11 | 1980-01-08 | Merck & Co., Inc. | Tetrazole derivatives of [1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy(or thio)]alkanoic acids |
| US4874777A (en) | 1987-04-10 | 1989-10-17 | Eli Lilly And Company | Leukotriene antagonists |
| US4845231A (en) | 1988-02-12 | 1989-07-04 | American Home Products Corporation | Tetrazoles and their use as hypoglycemic agents |
| FR2631827B1 (fr) | 1988-05-27 | 1992-03-27 | Delalande Sa | Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique |
| US5260322A (en) | 1990-10-08 | 1993-11-09 | Merck & Co., Inc. | Angiotension II antagonists in the treatment of hyperuricemia |
| US5591862A (en) | 1993-06-11 | 1997-01-07 | Takeda Chemical Industries, Ltd. | Tetrazole derivatives, their production and use |
| RU2144533C1 (ru) * | 1994-12-09 | 2000-01-20 | Такеда Кемикал Индастриз, Лтд. | Производные тетразола, способ их получения и фармацевтические композиции на их основе |
| EP0888278B1 (en) | 1996-02-02 | 2003-07-23 | Merck & Co., Inc. | Antidiabetic agents |
| BR9814087A (pt) | 1997-10-17 | 2000-10-03 | Aventis Pharm Prod Inc | Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente |
| EP1127882A1 (en) | 2000-01-25 | 2001-08-29 | Pfizer Products Inc. | Tetrazole compounds as thyroid receptor ligands |
| MXPA03011558A (es) | 2001-06-12 | 2004-03-26 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
| AU2003226094A1 (en) | 2002-03-27 | 2003-10-13 | Smithkline Beecham Corporation | Compounds and methods |
| US7087631B2 (en) * | 2002-07-18 | 2006-08-08 | Inotek Pharmaceuticals Corporation | Aryltetrazole compounds, and compositions thereof |
| US7078423B2 (en) | 2002-07-18 | 2006-07-18 | Inotek Pharmaceuticals Corporation | 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
| JP2004197711A (ja) * | 2002-12-20 | 2004-07-15 | Honda Motor Co Ltd | 回転流体機械 |
| EP1610812A1 (en) * | 2003-03-11 | 2006-01-04 | Novo Nordisk A/S | Pharmaceutical preparations comprising acid-stabilised insulin |
| AR051780A1 (es) | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| JP5339545B2 (ja) | 2008-03-13 | 2013-11-13 | ウェルスタット セラピューティクス コーポレイション | 尿酸を減少させる化合物及び方法 |
| MX2010011603A (es) | 2008-04-30 | 2011-01-25 | Wellstat Therapeutics Corp | Compuestos de tetrazol para reducir el acido urico. |
-
2009
- 2009-04-30 MX MX2010011603A patent/MX2010011603A/es active IP Right Grant
- 2009-04-30 US US12/989,724 patent/US8410154B2/en active Active
- 2009-04-30 RU RU2010148762/04A patent/RU2522458C2/ru active
- 2009-04-30 NZ NZ588374A patent/NZ588374A/xx not_active IP Right Cessation
- 2009-04-30 AU AU2009243028A patent/AU2009243028B2/en not_active Ceased
- 2009-04-30 WO PCT/US2009/042298 patent/WO2009134995A2/en not_active Ceased
- 2009-04-30 KR KR1020107024008A patent/KR101613611B1/ko not_active Expired - Fee Related
- 2009-04-30 CA CA2722624A patent/CA2722624C/en not_active Expired - Fee Related
- 2009-04-30 EP EP09739797.0A patent/EP2282736B1/en active Active
- 2009-04-30 ES ES09739797.0T patent/ES2561039T3/es active Active
- 2009-04-30 BR BRPI0910541A patent/BRPI0910541B8/pt not_active IP Right Cessation
- 2009-04-30 JP JP2011507641A patent/JP5431457B2/ja not_active Expired - Fee Related
- 2009-04-30 CN CN2009801155473A patent/CN102014898B/zh not_active Expired - Fee Related
-
2010
- 2010-09-29 ZA ZA2010/06929A patent/ZA201006929B/en unknown
- 2010-10-28 IL IL209004A patent/IL209004A/en active IP Right Grant
-
2013
- 2013-03-04 US US13/783,680 patent/US8889724B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009243028B2 (en) | 2015-01-29 |
| ZA201006929B (en) | 2011-06-29 |
| US8889724B2 (en) | 2014-11-18 |
| MX2010011603A (es) | 2011-01-25 |
| CA2722624A1 (en) | 2009-11-05 |
| US8410154B2 (en) | 2013-04-02 |
| EP2282736A4 (en) | 2011-06-15 |
| US20110206653A1 (en) | 2011-08-25 |
| EP2282736B1 (en) | 2015-11-11 |
| WO2009134995A2 (en) | 2009-11-05 |
| BRPI0910541B8 (pt) | 2021-05-25 |
| IL209004A0 (en) | 2011-01-31 |
| IL209004A (en) | 2014-04-30 |
| RU2522458C2 (ru) | 2014-07-10 |
| RU2010148762A (ru) | 2012-06-10 |
| ES2561039T3 (es) | 2016-02-24 |
| EP2282736A2 (en) | 2011-02-16 |
| KR101613611B1 (ko) | 2016-04-19 |
| CA2722624C (en) | 2017-03-21 |
| WO2009134995A3 (en) | 2009-12-23 |
| JP5431457B2 (ja) | 2014-03-05 |
| KR20100135851A (ko) | 2010-12-27 |
| JP2011519865A (ja) | 2011-07-14 |
| CN102014898B (zh) | 2013-01-23 |
| AU2009243028A1 (en) | 2009-11-05 |
| CN102014898A (zh) | 2011-04-13 |
| BRPI0910541B1 (pt) | 2019-12-03 |
| HK1147446A1 (en) | 2011-08-12 |
| US20130336949A1 (en) | 2013-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ588374A (en) | Tetrazole compounds for reducing uric acid | |
| NZ587433A (en) | Compounds and method for reducing uric acid | |
| EA018193B3 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| NZ593413A (en) | Combinations comprising methotrexate and dhodh inhibitors | |
| MA32468B1 (fr) | Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k | |
| TNSN07305A1 (fr) | Agonistes de pyy et leurs utilisations | |
| EA200900812A1 (ru) | Производные 4-имидазолил-1,2,3,4-тетрагидрохинолина и их применение в качестве ингибиторов альдостерон/11-бета-гидроксилазы | |
| JP2011515349A5 (https=) | ||
| MA30602B1 (fr) | Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs | |
| MY157525A (en) | Inhibitors of the renal outer medullary potassium channel | |
| NO20083567L (no) | Hydantoinderivater for behandling av inflammatoriske forstyrrelser | |
| WO2010028192A8 (en) | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors | |
| EA201070164A1 (ru) | Твердый препарат, включающий алоглиптин и гидрохлорид метформина | |
| WO2011011882A8 (en) | Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis | |
| MA34797B1 (fr) | Hétéroaryles et leurs utilisations | |
| EP2571876A4 (en) | SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES | |
| WO2009153665A3 (en) | Inhibitors of the shiga toxins trafficking through the retrograde pathway | |
| MX2009010893A (es) | Compuestos de xantina que tienen un efecto modulador del receptor gabab alosterico positivo. | |
| EP2595482A4 (en) | ALDOSTERONSYNTHASEHEMMER | |
| MA30351B1 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
| CO6710915A2 (es) | Composiciones farmacéuticas que contienen un inhibidor de dgat1 ácido 4-(4-(5-6(- trifluorometil-piridin -3- ilamino)-piridin- 2-il)fenil)cicloheiyl)-acético o sales del mismo | |
| CY1112270T1 (el) | Σπειρο βενζαζεπινες χρησιμες ως ανταγωνιστες αγγειοπιεσινης | |
| MX2011011080A (es) | Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida. | |
| GEP20125603B (en) | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents | |
| JP2009102616A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 APR 2016 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20131203 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2017 BY COMPUTER PACKAGES INC Effective date: 20160419 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2018 BY COMPUTER PACKAGES INC Effective date: 20170920 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2019 BY COMPUTER PACKAGES INC Effective date: 20180831 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2020 BY COMPUTER PACKAGES INC Effective date: 20190402 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2021 BY COMPUTER PACKAGES INC Effective date: 20200331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2022 BY COMPUTER PACKAGES INC Effective date: 20210917 |
|
| LAPS | Patent lapsed |